BIV vs IBB

Vanguard Intermediate-Term Bond ETF vs iShares Biotechnology ETF

Quick take
  • BIV has the lower expense ratio at 0.03% vs 0.44% for IBB.
  • BIV pays a higher dividend yield (4.20%).

Side-by-side metrics

MetricBIVIBB
Expense ratio
Annual fee. Lower is better.
0.03%0.44%
Dividend yield
Trailing 12-month yield.
4.20%0.22%
AUM
Assets under management — bigger funds are typically more liquid.
$52.51B$9.09B
YTD return
-0.38%16.44%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
1.030.69
P/E ratio
24.79
Last price
$76.19$196.62
Inception
Issuer
VanguardiShares

BIV top holdings

Holdings data unavailable for BIV.

IBB top holdings

Top holdings · IBB
VRTXVertex Pharmaceuticals Inc8.07%
AMGNAmgen Inc7.82%
GILDGilead Sciences Inc6.83%
REGNRegeneron Pharmaceuticals Inc4.90%
ARGXargenx SE ADR3.75%
ALNYAlnylam Pharmaceuticals Inc3.12%
NTRANatera Inc2.89%
RVMDRevolution Medicines Inc Ordinary Shares2.78%
BIIBBiogen Inc2.46%
ILMNIllumina Inc2.07%
Sector breakdown · IBB
Healthcare100.0%

About BIV

BIV (Vanguard Intermediate-Term Bond ETF) is Intermediate-term investment-grade bonds. Managed by Vanguard, the fund carries $52.5B in assets under management, an expense ratio of 0.03%, a dividend yield of 4.20%.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.